{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:22:03Z","timestamp":1792790523719,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["PdCCRS1128727"],"award-info":[{"award-number":["PdCCRS1128727"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["PdCCRS1128727"],"award-info":[{"award-number":["PdCCRS1128727"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["PdCCRS1128727"],"award-info":[{"award-number":["PdCCRS1128727"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["PdCCRS1128727"],"award-info":[{"award-number":["PdCCRS1128727"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["PdCCRS1128727"],"award-info":[{"award-number":["PdCCRS1128727"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["PdCCRS1128727"],"award-info":[{"award-number":["PdCCRS1128727"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["PdCCRS1128727"],"award-info":[{"award-number":["PdCCRS1128727"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["PdCCRS1128727"],"award-info":[{"award-number":["PdCCRS1128727"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["PdCCRS1128727"],"award-info":[{"award-number":["PdCCRS1128727"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Cancer Council NSW Program Grant PG16-01","id":[{"id":"https:\/\/ror.org\/05gsbkp40","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Kids Cancer Alliance 2020","id":[{"id":"https:\/\/ror.org\/00eqjcz31","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009553","name":"Agentura Pro Zdravotnick\u00fd V\u00fdzkum \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU21-03-00128"],"award-info":[{"award-number":["NU21-03-00128"]}],"id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      ABL-class fusions including\n                      <jats:italic>NUP214-ABL1<\/jats:italic>\n                      and\n                      <jats:italic>EBF1-PDGFRB<\/jats:italic>\n                      occur in high risk acute lymphoblastic leukaemia (ALL) with gene expression patterns similar to\n                      <jats:italic>BCR-ABL<\/jats:italic>\n                      -positive ALL. Our aim was to evaluate new DNA-based measurable residual disease (MRD) tests detecting these fusions and\n                      <jats:italic>IKZF1<\/jats:italic>\n                      -deletions in comparison with conventional immunoglobulin\/T-cell receptor (Ig\/TCR) markers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Precise genomic breakpoints were defined from targeted or whole genome next generation sequencing for ABL-fusions and\n                      <jats:italic>BCR-ABL1<\/jats:italic>\n                      . Quantitative PCR assays were designed and used to re-measure MRD in remission bone marrow samples previously tested using Ig\/TCR markers. All MRD testing complied with EuroMRD guidelines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      ABL-class patients had 46% 5year event-free survival and 79% 5year overall survival. All had sensitive fusion tests giving high concordance between Ig\/TCR and ABL-class fusion results (21 patients,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009257 samples, r2\u2009=\u20090.9786,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and Ig\/TCR and\n                      <jats:italic>IKZF1<\/jats:italic>\n                      -deletion results (9 patients,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009143 samples, r2\u2009=\u20090.9661,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). In contrast, in\n                      <jats:italic>BCR-ABL1<\/jats:italic>\n                      patients, Ig\/TCR and\n                      <jats:italic>BCR-ABL1<\/jats:italic>\n                      tests were discordant in 32% (40 patients,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009346 samples, r2\u2009=\u20090.4703,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and\n                      <jats:italic>IKZF1<\/jats:italic>\n                      -deletion results were closer to Ig\/TCR (25 patients,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009176, r2\u2009=\u20090.8631,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      MRD monitoring based on patient-specific assays detecting gene fusions or recurrent assays for\n                      <jats:italic>IKZF1<\/jats:italic>\n                      -deletions is feasible and provides good alternatives to Ig\/TCR tests to monitor MRD in ABL-class ALL.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-022-01806-6","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T15:02:33Z","timestamp":1654095753000},"page":"908-915","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions"],"prefix":"10.1038","volume":"127","author":[{"given":"Nicola C.","family":"Venn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libby","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Hovorkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Muskovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7497-6477","authenticated-orcid":false,"given":"Susan L.","family":"Heatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Lin","family":"Khaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Revesz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Dalla Pozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8062-1779","authenticated-orcid":false,"given":"Andrew S.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3103-9763","authenticated-orcid":false,"given":"Siobhan","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Bendak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0632-4589","authenticated-orcid":false,"given":"Murray D.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2741-3852","authenticated-orcid":false,"given":"Michelle J.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4844-333X","authenticated-orcid":false,"given":"Deborah L.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9519-5714","authenticated-orcid":false,"given":"Mark J.","family":"Cowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3295-228X","authenticated-orcid":false,"given":"Toby N.","family":"Trahair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Zuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0188-6005","authenticated-orcid":false,"given":"Rosemary","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"1806_CR1","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.3324\/haematol.2019.231720","volume":"105","author":"G Cario","year":"2020","unstructured":"Cario G, Leoni V, Conter V, Attarbaschi A, Zaliova M, Sramkova L, et al. Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. Haematologica. 2020;105:1887\u201394.","journal-title":"Haematologica"},{"key":"1806_CR2","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S2352-3026(20)30353-7","volume":"8","author":"ML den Boer","year":"2021","unstructured":"den Boer ML, Cario G, Moorman AV, Boer JM, de Groot-Kruseman HA, Fiocco M, et al. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. Lancet Haematol. 2021;8:e55\u2013e66.","journal-title":"Lancet Haematol"},{"key":"1806_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","volume":"371","author":"KG Roberts","year":"2014","unstructured":"Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371:1005\u201315.","journal-title":"N Engl J Med."},{"key":"1806_CR4","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1182\/blood.2019001244","volume":"134","author":"I Tanasi","year":"2019","unstructured":"Tanasi I, Ba I, Sirvent N, Braun T, Cuccuini W, Ballerini P, et al. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood. 2019;134:1351\u20135.","journal-title":"Blood."},{"key":"1806_CR5","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjh.17093","volume":"191","author":"AV Moorman","year":"2020","unstructured":"Moorman AV, Schwab C, Winterman E, Hancock J, Castleton A, Cummins M, et al. Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion. Br J Haematol. 2020;191:844\u201351.","journal-title":"Br J Haematol"},{"key":"1806_CR6","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/leu.2014.30","volume":"28","author":"KR Schultz","year":"2014","unstructured":"Schultz KR, Carroll A, Heerema NA, Bowman WP, Aledo A, Slayton WB, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children\u2019s Oncology Group Study AALL0031. Leukemia. 2014;28:1467\u201371.","journal-title":"Leukemia."},{"key":"1806_CR7","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood-2016-11-749978","volume":"129","author":"L Hovorkova","year":"2017","unstructured":"Hovorkova L, Zaliova M, Venn NC, Bleckmann K, Trkova M, Potuckova E, et al. Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. Blood. 2017;129:2771\u201381.","journal-title":"Blood."},{"key":"1806_CR8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/sj.leu.2404082","volume":"20","author":"T Burmeister","year":"2006","unstructured":"Burmeister T, Marschalek R, Schneider B, Meyer C, Gokbuget N, Schwartz S, et al. Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations. Leukemia. 2006;20:451\u20137.","journal-title":"Leukemia."},{"key":"1806_CR9","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/leu.2009.17","volume":"23","author":"VH Van der Velden","year":"2009","unstructured":"Van der Velden VH, Corral L, Valsecchi MG, Jansen MW, De Lorenzo P, Cazzaniga G, et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia. 2009;23:1073\u20139.","journal-title":"Leukemia."},{"key":"1806_CR10","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1056\/NEJMoa0808253","volume":"360","author":"CG Mullighan","year":"2009","unstructured":"Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470\u201380.","journal-title":"N Engl J Med."},{"key":"1806_CR11","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1182\/blood-2012-10-462358","volume":"122","author":"A van der Veer","year":"2013","unstructured":"van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood. 2013;122:2622\u20139.","journal-title":"Blood."},{"key":"1806_CR12","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/leu.2010.87","volume":"24","author":"RP Kuiper","year":"2010","unstructured":"Kuiper RP, Waanders E, van der Velden VHJ, van Reijmersdal SV, Venkatachalam R, Scheijen B, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia. 2010;24:1258\u201364.","journal-title":"Leukemia."},{"key":"1806_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3324\/haematol.2011.056135","volume":"98","author":"P Dorge","year":"2013","unstructured":"Dorge P, Meissner B, Zimmermann M, Moricke A, Schrauder A, Bouquin JP, et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica. 2013;98:428\u201332.","journal-title":"Haematologica."},{"key":"1806_CR14","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3324\/haematol.2012.075432","volume":"98","author":"C Palmi","year":"2013","unstructured":"Palmi C, Valsecchi MG, Longinotti G, Silvestri D, Carrino V, Conter V, et al. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? Haematologica. 2013;98:1226\u201331.","journal-title":"Haematologica."},{"key":"1806_CR15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/bjh.15056","volume":"180","author":"R Sutton","year":"2018","unstructured":"Sutton R, Venn NC, Law T, Boer JM, Trahair TN, Ng A, et al. A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children. Br J Haematol. 2018;180:550\u201362.","journal-title":"Br J Haematol"},{"key":"1806_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1182\/bloodadvances.2018025718","volume":"3","author":"L Hamadeh","year":"2019","unstructured":"Hamadeh L, Enshaei A, Schwab C, Alonso CN, Attarbaschi A, Barbany G, et al. Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL. Blood Adv. 2019;3:148\u201357.","journal-title":"Blood Adv."},{"key":"1806_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1182\/blood.2019000813","volume":"135","author":"M Stanulla","year":"2020","unstructured":"Stanulla M, Cave H, Moorman AV. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? Blood. 2020;135:252\u201360.","journal-title":"Blood."},{"key":"1806_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/leu.2015.199","volume":"30","author":"JM Boer","year":"2016","unstructured":"Boer JM, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, de Groot-Kruseman HA, et al. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. Leukemia. 2016;30:32\u20138.","journal-title":"Leukemia."},{"key":"1806_CR19","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/leu.2011.348","volume":"26","author":"NC Venn","year":"2012","unstructured":"Venn NC, van der Velden VH, de Bie M, Waanders E, Giles JE, Law T, et al. Highly sensitive MRD tests for ALL based on the IKZF1 Delta3-6 microdeletion. Leukemia. 2012;26:1414\u20136.","journal-title":"Leukemia."},{"key":"1806_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3324\/haematol.2012.073965","volume":"98","author":"A Caye","year":"2013","unstructured":"Caye A, Beldjord K, Mass-Malo K, Drunat S, Soulier J, Gandemer V, et al. Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2013;98:597\u2013601.","journal-title":"Haematologica."},{"key":"1806_CR21","doi-asserted-by":"publisher","first-page":"e490","DOI":"10.3324\/haematol.2016.162925","volume":"102","author":"SL Heatley","year":"2017","unstructured":"Heatley SL, Sadras T, Kok CH, Nievergall E, Quek K, Dang P, et al. High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Haematologica. 2017;102:e490\u2013e3.","journal-title":"Haematologica."},{"key":"1806_CR22","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41591-020-1072-4","volume":"26","author":"M Wong","year":"2020","unstructured":"Wong M, Mayoh C, Lau LMS, Khuong-Quang DA, Pinese M, Kumar A, et al. Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat Med. 2020;26:1742\u201353.","journal-title":"Nat Med."},{"key":"1806_CR23","unstructured":"Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at arXiv. 2013; https:\/\/arxiv.org\/abs\/1303.3997."},{"key":"1806_CR24","doi-asserted-by":"crossref","unstructured":"Cameron DL, Baber J, Shale C, Papenfuss AT, Valle-Inclan JE, Besselink N, et al. GRIDSS, PURPLE, LINX: unscrambling the tumor genome via integrated analysis of structural variation and copy number. Preprint at bioRxiv. 2019; https:\/\/www.biorxiv.org\/content\/10.1101\/781013v1.","DOI":"10.1101\/781013"},{"key":"1806_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 2012;6:80\u201392.","journal-title":"Fly (Austin)"},{"key":"1806_CR26","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1101\/gr.222109.117","volume":"27","author":"DL Cameron","year":"2017","unstructured":"Cameron DL, Schroder J, Penington JS, Do H, Molania R, Dobrovic A, et al. GRIDSS: sensitive and specific genomic rearrangement detection using positional de Bruijn graph assembly. Genome Res. 2017;27:2050\u201360.","journal-title":"Genome Res."},{"key":"1806_CR27","doi-asserted-by":"crossref","unstructured":"Shale C, Baber C, Cameron DL, Wong M, Cowley MJ, Papenfuss AT, et al. Unscrambling cancer genomes via integrated analysis of structural variation and copy number. Preprint for BioRxiv. 2020; https:\/\/www.biorxiv.org\/content\/10.1101\/2020.12.03.410860v1.","DOI":"10.1101\/2020.12.03.410860"},{"key":"1806_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjh.13142","volume":"168","author":"R Sutton","year":"2015","unstructured":"Sutton R, Shaw PJ, Venn NC, Law T, Dissanayake A, Kilo T, et al. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia. Br J Haematol. 2015;168:395\u2013404.","journal-title":"Br J Haematol."},{"key":"1806_CR29","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1182\/blood-2016-03-704973","volume":"128","author":"JA Irving","year":"2016","unstructured":"Irving JA, Enshaei A, Parker CA, Sutton R, Kuiper RP, Erhorn A, et al. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2016;128:911\u201322.","journal-title":"Blood."},{"key":"1806_CR30","doi-asserted-by":"crossref","unstructured":"Subhash VV, Huang L, Kamili A, Wong M, Chen D, Venn NC, et al. Whole genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma. British J Cancer. 2022;126;482\u201391.","DOI":"10.1038\/s41416-021-01538-z"},{"key":"1806_CR31","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/leu.2008.5","volume":"22","author":"T Flohr","year":"2008","unstructured":"Flohr T, Schrauder A, Cazzaniga G, Panzer-Gr\u00fcmayer R, van der Velden V, Fischer S, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22:771\u201382.","journal-title":"Leukemia."},{"key":"1806_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1182\/blood-2007-01-067785","volume":"110","author":"S Choi","year":"2007","unstructured":"Choi S, Henderson M, Kwan EN, Sutton R, Giles J, Venn NC, et al. Relapse in children with acute lymphoblastic leukaemia involving selection of a pre-existing drug resistant subclone. Blood. 2007;110:632\u20139.","journal-title":"Blood."},{"key":"1806_CR33","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"V van der Velden","year":"2007","unstructured":"van der Velden V, Cazzaniga G, Schrauder A, Hancock JF, Bader P, Panzer E, et al. Analysis of minimal residual disease by Ig\/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604\u201311.","journal-title":"Leukemia."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01806-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01806-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01806-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T19:09:33Z","timestamp":1661886573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01806-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9,1]]}},"alternative-id":["1806"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01806-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"17 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and the NHMRC Australia National Statement on Ethical Conduct in Human Research (2007). It used leftover samples from paediatric ALL patients, all with signed parental consent for MRD testing and future research. approved Both the research on new MRD markers to improve stratification (2019\/ETH06161) and the parental information and consent forms (LNR\/13\/SCHN\/392) were approved by the Sydney Children\u2019s Hospital Network Human Research Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Parents of all patients had signed consent for publication of future research in a format that does not identify the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}